Aim: The aim of this study is to evaluate the efficacy and complications of subconjunctival Botulinum toxin type- A (BTA) injection, for the management of upper eyelid retraction asso- ciated with dysthyroid ophthalmopathy. Material and Method: In this study, 33 eyes of 27 patients with upper eyelid retraction due to dysthyroid ophthalmopathy, were reviewed retrospectively according to the photographs taken under standardized conditions. Sixteen female and 11 male patients with mean age 41 ±10.9 (25-63) were in the euthyroid state. Patients had complete ophthalmic examinations and margin-reflex distances were measured before injection. BTA was injected subconjunctivally, just above the superior tarsal border of the upper eyelid in doses between 2-15 IU, depending on the measured retraction amount. 7-10 days after injection margin- reflex distances were measured. Two to four IU BTA injections were repeated in patients who were undercorrected. All patients were followed for margin reflex distance measurements regularly for 4 to 6 months. All complications, such as pain, diplopia, ptosis, and orbicularis insufficiency were also recorded. Results: After Botulinum Toxin-A injections, targeted margin-reflex distance, which is 3-4 mm, was reached in the 23 of 33 eyes (69.6%). 8 eyes (24%) who had remaining lid retraction more than 50% of preinjection retraction amount were re-injected again on the tenth day. 0.5 mm increase in retraction was seen only in one eye Ptosis was observed in 3 eyes. Upper eye- lid retraction, close to the preinjection measurements, recurred after 4-6 months in all patients. Side effects resolved spontaneously in 4 months without sequelae. Conclusion: In dysthyroid ophthalmopathy, subconjunctival injection of Botulinum toksin A is an effective, safe, transient, and repeatable method with few complications during the waiting period before lid surgery.